The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is an emerging clinical problem. Hence, in this study, the plausible role of extended-spectrum beta-lactamases (ESBLs)/carbapenemases, OmpC/Ompk36, acrB and their combinations was explored among CRE.
retain in vitro activity against carbapenem-resistant Enterobacteriaceae (CRE), their usages are restricted by either their side effect profile or uncertainty of in vivo efficacy 3 . From 2008 onwards, resistance towards several widely used carbapenems, namely imipenem, meropenem and ertapenem, had increased significantly in India 4 . While, only 11-22 per cent of enterobacterial isolates were found to be resistant towards at least one of these three carbapenems during [2007] [2008] , such resistance has been found to rise to at least 37.9 per cent in recent years 4, 5 .
Combined expression of extended-spectrum beta-lactamase (ESBL)-type enzymes with either loss/reduced expression of major outer membrane proteins (OMPs) (OmpF/Ompk35 of MW 36kDa and OmpC/Ompk36 of MW 38kDa in Escherichia coli/ Klebsiella spp., respectively) or overexpression of efflux pumps (AcrAB-TolC) as well as expression of metallo (NDM; VIM)/non-metallo-beta-lactamase (KPC; OXA)-type carbapenemases alone was known to be responsible for carbapenem resistance development among pathogenic Enterobacteriaceae 4, 6, 7 . However, the nature of contribution of these mechanisms towards carbapenem resistance development, whether additive, augmentative or diminutive, has not yet been well documented. Although the association of expression of porins and efflux pumps with ESBL is well known for carbapenem resistance development, but their relation with carbapenemases has not been studied before. Besides, reports on contribution of all these mechanisms for such resistance development among isolates of Indian origin are limited. Thus, the present cross-sectional study was undertaken to address all the aforesaid lacunae for better understanding the increasing emergence of CRE in India.
Material & Methods
Enterobacterial samples were obtained from urine, blood, sputum, body fluid, wound and pus of different non-duplicate and unrelated patients visiting the outpatient department of Seth Sukhlal Karnani Memorial Hospital-Institute of Post Graduate Medical Education and Research (SSKM-IPGMER) and Calcutta School of Tropical Medicine (CSTM, Kolkata, India), from May 2013 to October 2016. Samples were subjected to Gram staining and streaked on nutrient agar, blood agar and MacConkey's agar media and incubated overnight at 37ºC. Identification of E. coli and Klebsiella spp. isolates was done by growing isolates on organism-specific HiCrome™ selective agar (HiMedia Laboratories Pvt. Ltd., India) as well as by standard biochemical methods 8 . 9 , for the following antimicrobial agents (µg/disc): ceftazidime (30) , cefotaxime (30) , cefpodoxime (10), imipenem (10), meropenem (10) and ertapenem (10) (HiMedia Laboratories Pvt. Ltd., Mumbai). Isolates resistant and non-resistant to all carbapenems were categorized as Group I (resistant to all carbapenems) and Group II (non-resistant to all the carbapenems), respectively. The minimum inhibitory concentration (MIC) value (mg/l) of meropenem (AstraZeneca, UK) against Groups I and II isolates was determined using microdilution method and interpreted according to the guidelines of CLSI 9 .
Phenotypic characterization of Group I and Group II isolates: Screening of ESBLs was done according to the guidelines of CLSI 9 . Isolates exhibiting an increase of >5 mm in inhibition zone of the combined ceftazidime/cefotaxime (30 µg)-clavulanic acid (10 µg) disc, compared to ceftazidime/cefotaxime (30 µg) alone, were categorized as ESBL positive. Carbapenemase activity was assayed among these isolates following the protocol described by Bernabeu et al 10 . Briefly, the isolates were sonicated and the supernatant was used to determine meropenem-hydrolyzing activity spectrophotometrically. Percentage activity was calculated by the following formula: Detection of metallo-β-lactamases (MBLs) among isolates with carbapenemase activity was evaluated by double-disc synergy test (DDST) 4 , where imipenem (10 µg) and imipenem-ethylenediaminetetraacetic acid (10/750 µg) combination disc (HiMedia Laboratories Pvt. Ltd., Mumbai) were placed 40-50 mm apart over the lawn of bacteria, spread aseptically over Mueller-Hinton agar and incubated overnight at 37°C 4 . Isolates exhibiting an increase of >5 mm in the inhibition zone of the combination disc, compared to imipenem alone, were categorized as MBL positive.
Genomic DNA isolation, PCR detection of ESBLs and carbapenemases:
Plasmid and chromosomal DNA was extracted from Groups I and II isolates by alkaline lysis and Hancock's method, respectively 11, 12 . PCR amplification was carried out for detection of the following ESBL, MBL and non-MBL genes -ESBL: bla TEM, bla SHV and bla CTX-M ; MBL: bla NDM and bla VIM and non-MBL: bla KPC and bla OXA-48 -like variants using DNA and gene-specific primers, designed through Primer3 server, web version 4.0.0 (http://bioinfo.ut.ee/primer3/) ( Table I ). Based on PCR data, Group I isolates were further genotypically categorized into four subgroups, namely ESBL only (Ia), carbapenemase only (Ib), both ESBL and carbapenemase-producing (Ic) and none present (Id).
Analysis of expression of acrB efflux pump gene: Group I and II isolates were grown in Müller-Hinton Broth at 37°C with continuous orbital shaking and harvested at mid-log phase by centrifugation 12,300 × g 10 min.
Bacterial total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and was reverse transcribed to cDNA by first-strand cDNA synthesis kit (Thermo Fisher Scientific Inc., MA, USA) following manufacturer's standard protocols. Expression of acrB was normalized against that of housekeeping gene, RNA polymerase B (rpoB), used as internal control 13 . The level of acrB expression among isolates of different subgroups was determined by calculating 2 −∆∆CT and compared to that of Group II isolates, using DataAssist™ software v2.1 (Thermo Fisher Scientific Inc., USA).
Analysis of bacterial outer membrane protein (OMP)
expression: Group I and group II isolates were grown in Müller-Hinton Broth at 37ºC with continuous orbital shaking and harvested at mid-log phase by centrifugation at 12,300 × g 10 min. Bacterial OMPs were isolated and purified following the protocols described earlier 14 .
OMPs were quantified in Lowry's method 15 . About 100 µg of OMPs/well were separated by 15 per cent sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by staining using 0.25 per 17 . The statistical analyses were performed through SPSS software v17.0 (IBM Inc., NY, USA). Overall contribution of all the strategies, namely expression of beta-lactamases (B: ESBL; C: carbapenemases), efflux pump's upregulation (E) and porin loss (P) and their combinations in carbapenem resistance development was represented through proportionate Venn diagram by eulerAPE v3.0.0 18 . (Table II) . These genes were mostly found among ESBL only and both ESBL-and carbapenemase-producing phenotypes. Distribution of beta-lactamase genes among different phenotypic groups is elaborated in (Table IV) . Moreover, single and multiple gene harbouring isolates among Klebsiella spp. of subgroup Ib revealed marked difference in their meropenemhydrolyzing proficiency (P<0.01).
Results

From
Inter subgroup comparison revealed significant overexpression of acrB among beta-lactamase-producing E. coli of subgroups Ia, Ib and Ic with respect to Id (no beta-lactamase gene present) (P<0.05) (Table IV) . However, this trend was not followed among Klebsiella spp., where acrB gene was found to be slightly underexpressed among these subgroups.
Comparable expression of OmpC was documented among all the subgroups of E. coli, whereas significant loss/reduced expression of Ompk36 was found among Id Klebsiella spp. (no beta-lactamase gene present) when compared to beta-lactamase-producing Klebsiella spp. of subgroups Ia, Ib and Ic (P<0.01) ( Table IV) .
Role of different strategies in carbapenem resistance emergence:
Although the presence of only ESBL/ carbapenemase genes (B/C), efflux pump upregulation (E), porin loss (P) or their combinations, namely B/C-E, B/C-P, PE and B/C-PE exhibited differential contribution in carbapenem resistance emergence among E. coli and Klebsiella spp., PE (10/34: 29.41%), B/C-PE (11/34: 32.35%) of E. coli and B/C-E (18/59: 30.51%), B/C-P (13/59: 22.03%) and PE (13/59: 22.03%) of Klebsiella spp. were found to be the most predominant strategies (Fig. 2A) . Most of these isolates following these predominant strategic combinations exhibited very high level of meropenem resistance (MIC >1024 mg/l), whereas isolates with only B/C strategy demonstrated low level of meropenem resistance (MIC: 64-256 mg/l) indicating the major role of P, E and their combined strategies to increase meropenem resistance (one-way ANOVA: P<0.01; post hoc Tukey's HSD test: P<0.01 for all the six strategies including P, E and their combinations with respect to B/C alone) (Fig. 2B) . Single (1) 512 ( Ib E. coli (13) Single (9) >1024 ( Klebsiella spp. (27) Single (22) >1024 (72.7) 7.48±1.98
13.93±3.78
18.53±5.30 [11] Multiple (5) >1024 ( Overall (10) >1024 (50.0) Table V) . Unlike this mechanism, Klebsiella spp. of subgroups Ia following PE strategy had higher level of acrB upregulation when compared to those following E strategy within the same subgroups -indicating the positive role of Ompk36 in augmenting acrB upregulation (one-way ANOVA: P<0.05). These two findings implicated mutual complementation of P and E among Ia, Ib and Ic isolates following PE strategy.
Discussion
In this study, majority of the CREs were isolated from urinary infections, treatment of which renders a serious challenge to clinicians. As most of the CREs isolated from urine exhibited resistance to aminoglycosides, fluoroquinolones and carbapenems -commonly used to treat urologic infections, there is an increased risk of receiving inappropriate empiric treatment, thereby resulting in higher rate of morbidity/morality associated with CRE infections 19, 20 . Although treatment options are limited, old antibiotics -temocillin, fosfomycin, pivmecillinam, ceftolozane-tazobactum and combination therapywere often recommended as available line of treatment against such infections 20 .
Similar to a previous study by Dhara and Tripathi 21 in the current study phenotypic screening identified ESBL property among majority of the isolates. The presence of carbapenemase activity and bla NDM indicated their contribution towards the emergence of P<0.01) . B/C, ESBL/ Carbapenemases; P, porin loss; E, efflux pump's upregulation; CP, carbapenemase expressing isolates with porin loss; CE, carbapenemase expressing isolates with efflux pump's upregulation; PE, both porin loss and efflux pump's upregulation; CPE, carbapenemase expressing isolates with both porin loss and efflux pump's upregulation. [22] [23] [24] . Besides, rare co-existence of bla OXA-48 -like variants and bla NDM genes was noted among carbapenem-resistant E. coli isolates, which was consistent with the earlier findings 25 .
Although previous studies reported the additive role of ESBL production, decreased OMP expression and an active efflux pump system towards carbapenem resistance development, association of carbapenemases with OMP loss and acrB upregulation was not explored before [26] [27] [28] . In addition to exploring the wellknown association between ESBL production and acrB upregulation/porin loss, a significant association of carbapenemase production with acrB upregulation was observed in the current study among CREs. Although similar significant association between ampC production and efflux pump upregulation was reported among Pseudomonas aeruginosa previously 29 , there is no report of such association among CREs. Significant association between ESBL/carbapenemase production and OmpC/Ompk36 reduction was also found in the present study, which was consistent with the results of Wozniak et al 30 . The current study demonstrated the positive role of acrB in augmenting OmpC reduction among carbapenem-resistant E. coli and that of Ompk36 in facilitating acrB upregulation among carbapenem-resistant Klebsiella spp. The overall study indicated greater contribution of Ompk36 loss over acrB expression, particularly among Klebsiella spp. Similar association between the presence of IMP-4 MBL production and loss of Ompk36 was reported in carbapenem-resistant Klebsiella oxytoca isolate ZC101 of Chinese origin 31 . In the present study, isolates having no ESBL and carbapenemase activities demonstrated minimal acrB overexpression and OmpC/Ompk36 loss. Thus, ESBL or carbapenemase production only in combination with acrB overexpression and porin downregulation could have played a major role in imparting carbapenem resistance among these bacteria.
Though difference in carbapenemase activity was noted among inter subgroups (Ia-Id), but mode MIC value against meropenem remained almost consistent all throughout indicating the secondary role of carbapenemases and the contribution of other mechanisms in imparting carbapenem resistance among these subgroups. Though similar findings were reported earlier among pathogenic Pseudomonas aeruginosa 32 , such observations were not reported for CRE. This was also evident on comparing the role of different strategies on MIC values of meropenem. In case of both E. coli and Klebsiella spp., presence of only ESBL/carbapenemases imparted MIC of meropenem within only 64-256 mg/l range, whereas the presence of ESBL/carbapenemases along with porin loss and/or efflux pump activation heightened the MIC value above 256 mg/l. All these findings indicated the contribution of efflux pump activation and porin loss over the presence of ESBLs/carbapenemases towards imparting carbapenem resistance among pathogenic enterobacterial isolates. Since the drugs targeting these mechanisms are limited in commercial markets, targeted mechanisms towards porin loss and efflux pump activation must be developed to address the carbapenem resistance issue of pathogenic bacteria.
